Lite Strategy is no longer an oncology developer in any economic sense. The San Diego issuer that used to trade as MEI Pharma spent the past year converting a leftover public listing into a Nasdaq wrapper for Litecoin, the silver-to-Bitcoin payments coin created by Charlie Lee. The equity now lives or dies on three things that compound rather than offset: the spot price of that single coin, whether management can buy back stock cheaper than the coin stack is worth, and whether the company stops selling the stack to pay for the wrapper. The market is not pricing a biotech option. It is pricing a closed-end Litecoin fund that has already given back more than half the purchase cost of its reserve and is still shrinking the pile.
The July private placement, a PIPE that raised $100 million by issuing new common stock and pre-funded warrants, funded the entire reserve in one stroke. Management then spent that cash on Litecoin and invited Lee and a GSR Markets strategist onto the board. The more recent and more revealing move is the buyback. From December through mid-July the company retired about 13 percent of the starting share count and paid for those purchases by selling coins and writing covered calls, which are options that collect a premium now in exchange for capping upside on the coins already owned. That is not a treasury accumulating a reserve. That is a treasury consuming the reserve to close a discount.
The March quarter showed how the accounting now works. Fair-value rules push every swing in the coin through the income statement, and the nine-month loss was dominated by a mark that cut the purchased reserve nearly in half. Cash also thinned as the operating shell and the repurchase program drew on both the bank account and the coin account. The tension is simple and ugly: buying back stock below net asset value, the per-share worth of cash plus coins minus liabilities, is accretive only while enough coins remain to make the remaining shares more valuable. Sell too many coins to fund the buyback and the accretion becomes a wash.
What resolves the debate is observable inside a few quarters. Either Litecoin recovers enough that the wrapper trades closer to the stack, and buybacks at a residual discount still lift coins per remaining share, or the coin stays depressed, the discount re-widens, and further repurchases require still more liquidations. The next test is whether unit holdings stabilize. A reserve that keeps shrinking while the stock still sits under the implied coin value is not compounding. It is distributing the remaining pile through a public listing.